Abstract: The present disclosure relates to ophthalmic compositions comprising solid complexes of active pharmaceutical ingredient, in particular kinase inhibitors and cyclodextrin, and to their uses in the treatment of posterior ocular conditions. More specifically, the disclosure relates to an aqueous composition comprising drug/cyclodextrin complexes of a tyrosine kinase inhibitor or a salt thereof, and a cyclodextrin, wherein said complexes have a complexation efficacy (CE) of more than 0.01, preferably more than 0.1 in the aqueous composition, and/or the tyrosine kinase inhibitor or a salt thereof has a ratio of the half maximal inhibitory concentration (IC50) of the epidermal growth factor receptors (EGFR) to the half maximal inhibitory concentration (IC50) of the vascular endothelial growth factor receptors (VEGFR2) that is greater than 2000, preferably greater than 5000.

Abstract: An anti-viral composition or formulation is described that includes free fatty acids (“FFA”). Also described, are methods of making and using such a composition or formulation.

Abstract: A method and an apparatus for detecting change in retinal oxygen saturation over time are provided. The method includes the steps of capturing a first group of images of two or more wavelengths, calculating oxygen saturation of a vessel in the first group of images, storing the first group of images on a data storage device, capturing a second group of images of two or more wavelengths, calculating the oxygen saturation of a vessels in the second group of images, storing the second group of images on a data storage device, spatially registering the pair of the group of images, captured at different time and calculate the change in oxygen saturation. The method also includes means to validate whether an observed change in oxygen saturation is a real physiological change or artificial.

Abstract: The invention relates to fatty acid stimulation of rectal mucosa initiating the process of defecation, acting as a laxative. Furthermore, the invention relates to the usage of free fatty acids, fatty acid mixtures and fatty acid extracts from marine lipids in pharmaceutical formulations such as suppositories, ointments, tablets and gelatin capsules for treatment and prevention of multiple disorders like constipation, hemorrhoids, bacterial infections (e.g. helicobacter pylori), viral infections (e.g. herpes simplex virus infections) and inflammations, as well as against fissura ani and pruritus ani.

Abstract: The invention provides an ophthalmic composition which is an aqueous suspension comprising drug, cyclodextrin and water, the composition having an aqueous phase of from about 0.1% (w/v) to about 90% (w/v) of the drug in solution, as dissolved free drug and as dissolved drug/cyclodextrin complex(es), and a solid phase of from about 10% (w/v) to about 99.9% (w/v) of the drug as solid drug/cyclodextrin particles, suspended in the aqueous phase; the size of the solid particles being from about 10 nm to about 1 mm, the drug/cyclodextrin particles being capable of dissolving in aqueous tear fluid within 24 hours of application to the eye surface. The aqueous eye suspension can be in the form of eye drops, eye gel or eye mist.

Abstract: The invention provides an ophthalmic composition which is an aqueous suspension comprising drug, cyclodextrin and water, the composition having an aqueous phase of from about 0.1% (w/v) to about 90% (w/v) of the drug in solution, as dissolved free drug and as dissolved drug/cyclodextrin complex(es), and a solid phase of from about 10% (w/v) to about 99.9% (w/v) of the drug as solid drug/cyclodextrin particles, suspended in the aqueous phase; the size of the solid particles being from about 10 nm to about 1 mm, the drug/cyclodextrin particles being capable of dissolving in aqueous tear fluid within 24 hours of application to the eye surface. The aqueous eye suspension can be in the form of eye drops, eye gel or eye mist.

Abstract: The invention provides an ophthalmic composition which is an aqueous suspension comprising drug, cyclodextrin and water, the composition having an aqueous phase of from about 0.1% (w/v) to about 90% (w/v) of the drug in solution, as dissolved free drug and as dissolved drug/cyclodextrin complex(es), and a solid phase of from about 10% (w/v) to about 99.9% (w/v) of the drug as solid drug/cyclodextrin particles, suspended in the aqueous phase; the size of the solid particles being from about 10 nm to about 1 mm, the drug/cyclodextrin particles being capable of dissolving in aqueous tear fluid within 24 hours of application to the eye surface. The aqueous eye suspension can be in the form of eye drops, eye gel or eye mist.

Abstract: The invention provides an ophthalmic composition which is an aqueous suspension comprising drug, cyclodextrin and water, the composition having an aqueous phase of from about 0.1% (w/v) to about 90% (w/v) of the drug in solution, as dissolved free drug and as dissolved drug/cyclodextrin complex(es), and a solid phase of from about 10% (w/v) to about 99.9% (w/v) of the drug as solid drug/cyclodextrin particles, suspended in the aqueous phase; the size of the solid particles being from about 10 nm to about 1 mm, the drug/cyclodextrin particles being capable of dissolving in aqueous tear fluid within 24 hours of application to the eye surface. The aqueous eye suspension can be in the form of eye drops, eye gel or eye mist.

Abstract: The invention relates to fatty acid stimulation of rectal mucosa initiating the process of defecation, acting as a laxative. Furthermore, the invention relates to the usage of free fatty acids, fatty acid mixtures and fatty acid extracts from marine lipids in pharmaceutical formulations such as suppositories, ointments, tablets and gelatin capsules for treatment and prevention of multiple disorders like constipation, hemorrhoids, bacterial infections (e.g. helicobacter pylori), viral infections (e.g. herpes simplex virus infections) and inflammations, as well as against fissura ani and pruritus ani.

Abstract: The present invention discloses methods, computer program and system to overcome the limitation of the current clinical practice. This is achieved by using information technology and the vast amount of epidemiological data available to create algorithms that calculate the risk or severity profile of an individual with any given disease. The individual profile presents the current condition and/or position of the individual in comparison with the mean base curve of the total population and in accordance with upper and lower risk limits. The individual profile is then fitted with its optimal use of healthcare resources, such as medication, surgery, laser treatment, surveillance and follow-up, to optimize and individualize the health outcome of this individual, and at the same time optimize and individualize the allocation of healthcare resources within the system.

Abstract: The invention provides an ophthalmic composition which is an aqueous suspension comprising drug, cyclodextrin and water, the composition having an aqueous phase of from about 0.1% (w/v) to about 90% (w/v) of the drug in solution, as dissolved free drug and as dissolved drug/cyclodextrin complex(es), and a solid phase of from about 10% (w/v) to about 99.9% (w/v) of the drug as solid drug/cyclodextrin particles, suspended in the aqueous phase; the size of the solid particles being from about 10 nm to about 1 mm, the drug/cyclodextrin particles being capable of dissolving in aqueous tear fluid within 24 hours of application to the eye surface. The aqueous eye suspension can be in the form of eye drops, eye gel or eye mist.

Abstract: The invention provides an ophthalmic composition which is an aqueous suspension comprising drug, cyclodextrin and water, the composition having an aqueous phase of from about 0.1% (w/v) to about 90% (w/v) of the drug in solution, as dissolved free drug and as dissolved drug/cyclodextrin complex(es), and a solid phase of from about 10% (w/v) to about 99.9% (w/v) of the drug as solid drug/cyclodextrin particles, suspended in the aqueous phase; the size of the solid particles being from about 10 nm to about 1 mm, the drug/cyclodextrin particles being capable of dissolving in aqueous tear fluid within 24 hours of application to the eye surface. The aqueous eye suspension can be in the form of eye drops, eye gel or eye mist.

Abstract: The example embodiments relate to a system for automatically evaluating oxygen saturation of the optic nerve and retina, including an image capturing system which includes a fundus camera, a four wavelengths beam splitter, a digital image capturing device, a computer system, and image processing software for registering and analyzing multi-spectral images of the retina, and for evaluating oxygen saturation level.

Abstract: The invention relates to fatty acid stimulation of rectal mucosa initiating the process of defecation, acting as a laxative. Furthermore, the invention relates to the usage of free fatty acids, fatty acid mixtures and fatty acid extracts from marine lipids in pharmaceutical formulations such as suppositories, ointments, tablets and gelatin capsules for treatment and prevention of multiple disorders like constipation, hemorrhoids, bacterial infections (e.g. helicobacter pylori), viral infections (e.g. herpes simplex virus infections) and inflammations, as well as against fissura ani and pruritus ani.

Abstract: This invention relates to a stable pharmaceutical formulation containing olanzapine. The composition comprises olanzapine or a pharmaceutically acceptable salt thereof, one or more suitable pharmaceutical excipients and a compound of formula (I) and/or a compound of formula (II): or a pharmaceutically acceptable salt thereof.

Abstract: This invention relates to a stable pharmaceutical formulation containing olanzapine. The composition comprises olanzapine or a pharmaceutically acceptable salt thereof, and one or more suitable pharmaceutical excipients, wherein the composition is coated with a coating comprising polyvinyl alcohol.

Abstract: The invention provides an ophthalmic composition which is an aqueous suspension comprising drug, cyclodextrin and water, the composition having an aqueous phase of from about 0.1% (w/v) to about 90% (w/v) of the drug in solution, as dissolved free drug and as dissolved drug/cyclodextrin complex(es), and a solid phase of from about 10% (w/v) to about 99.9% (w/v) of the drug as solid drug/cyclodextrin particles, suspended in the aqueous phase; the size of the solid particles being from about 10 nm to about 1 mm, the drug/cyclodextrin particles being capable of dissolving in aqueous tear fluid within 24 hours of application to the eye surface. The aqueous eye suspension can be in the form of eye drops, eye gel or eye mist.

Abstract: The present invention relates to a system for automatically evaluating oxygen saturation of the optic nerve and retina, said system comprising: image capturing system further comprising: a fundus camera (26), a four wavelengths beam splitter (27), a digital image capturing device (28), a computer system, image processing software performing in real-time the steps of: registering set of multi-spectral images (1) by, binarizing the multi-spectral image (7), find the all the border regions of each image by finding the region including the straight line that passes the most number of points in the region (8), use the orientation of the borders to evaluate the orientation of each spectral image (9), equalize the orientation of each spectral image by rotating the spectral image (10), edge detect each spectral image (11), estimate the translation between the spectral images based on the edges of adjacent images (12), transform the images to a stack of registered images (13), locating blood vessels (2) in each of the

Abstract: Methods for enhancing the complexation efficiency of a drug with cyclodextrin and for enhancing the availability of a drug following administration of a cyclodextrin-drug complex.

Abstract: Methods for enhancing the complexation efficiency of a drug with cyclodextrin and for enhancing the availability of a drug following administration of a cyclodextrin-drug complex.